前列腺切除术后的辅助与挽救性放疗:ASTRO/AUA指南2018-2019年修订版
本修订版将新发表文献纳入原ASTRO/AUA前列腺切除术后辅助与挽救性放疗指南,系统评价纳入1990年1月至2017年12月发表的155篇参考文献,新增两个关键问题(基因组分类器应用和根治性前列腺切除术后寡转移放疗)。新增关于挽救性放疗联合激素治疗的声明,并用长期数据更新辅助放疗的现有声明。结论:对根治性前列腺切除术后适合挽救性放疗的患者应提供激素治疗,决策应由患者和多学科团队共同做出。
要点
- 对根治性前列腺切除术后适合挽救性放疗的患者,应提供激素治疗。
- 临床医生应与患者讨论可能的短期和长期副作用以及预防复发的潜在获益。
- 激素治疗决策应由患者和多学科团队共同做出,充分考虑患者病史、价值观、偏好、生活质量和功能状态。
核心结论
- 对根治性前列腺切除术后适合挽救性放疗的患者应提供激素治疗。
- 临床医生应与患者讨论可能的短期和长期副作用以及预防复发的潜在获益。
- 激素治疗决策应由患者和多学科团队共同做出,充分考虑患者病史、价值观、偏好、生活质量和功能状态。
研究设计与样本
- 本指南修订版由ASTRO/AUA制定,将新发表文献纳入原指南并更新临床框架。
- 原系统评价纳入1990年1月至2012年12月发表的294项研究。
- 2018年4月修订版纳入1990年1月至2017年12月发表的155篇参考文献。
- 新增两个关键问题:基因组分类器的使用和根治性前列腺切除术后寡转移的放疗。
主要发现
- 新增关于根治性前列腺切除术后挽救性放疗联合激素治疗的声明。
- 使用长期数据更新了关于辅助放疗的现有声明。
- 其余指南声明被重申,并在现有文献库中增加参考文献。
- 在未来研究讨论中增加了基因组分类器作为风险分层工具的讨论。
- 未发现关于寡转移的相关数据。
关键数值与推荐
- 对根治性前列腺切除术后适合挽救性放疗的患者应提供激素治疗。
- 临床医生应与患者讨论可能的短期和长期副作用以及预防复发的潜在获益。
- 激素治疗决策应由患者和多学科团队共同做出,充分考虑患者病史、价值观、偏好、生活质量和功能状态。
临床怎么用
- 对根治性前列腺切除术后适合挽救性放疗的患者,应提供激素治疗。
- 应与患者讨论激素治疗的短期和长期副作用以及预防复发的潜在获益。
- 激素治疗决策应由患者和多学科团队共同做出,综合考虑患者病史、价值观、偏好、生活质量和功能状态。
局限性
- 未发现关于寡转移的相关数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The purpose of this amendment is to incorporate newly-published literature into the original ASTRO/AUA Adjuvant and Salvage Radiotherapy after Prostatectomy Guideline and to provide an updated clinical framework for clinicians. MATERIALS AND METHODS: The original systematic review yielded 294 studies published between January 1990 and December 2012. In April 2018, the guideline underwent an amendment and incorporated 155 references that were published from January 1990 through December 2017. Two new key questions were added. One on the use of genomic classifiers and the other on the treatment of oligo-metastases with radiation post-radical prostatectomy. RESULTS: A new statement on the use of hormone therapy with salvage radiotherapy after radical prostatectomy was added and long-term data was used to update an existing statement on adjuvant radiotherapy. The balance of the guideline statements were re-affirmed and references were added to the existing literature base. A discussion on the use of genomic classifiers as a risk stratification tool was added to the future research discussion. No relevant data on oligo-metastases was found. CONCLUSIONS: Hormone therapy should be offered to patients who have had radical prostatectomy and who are candidates for salvage radiotherapy. The clinician should discuss possible short- and long-term side effects with the patient as well as the potential benefits of preventing recurrence. The decision to use hormone therapy should be made by the patient and a multi-disciplinary team of providers with full consideration of the patient's history, values, preferences, quality of life, and functional status.
引用
- Pisansky TM, Thompson IM, Valicenti RK, et al. Adjuvant and Salvage Radiotherapy after Prostatectomy: ASTRO/AUA Guideline Amendment 2018-2019. J Urol. 2019. PMID: 31042111. doi:10.1097/JU.0000000000000295
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。